

Table 1.23
Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sites^a by Race/Ethnicity
Both Sexes

	All Races		White		Black		
	Rate ^b 2013-2017	APC ^c 2008-2017	Rate ^b 2013-2017	APC ^c 2008-2017	Rate ^b 2013-2017	APC ^c 2008-2017	
All Sites	442.4	-1.1*	452.1	-1.1*	440.4	-1.6*	
Breast	68.9	0.0	69.5	-0.2	Prostate ^f	74.4	-4.2*
Lung and Bronchus	54.2	-2.2*	56.0	-2.2*	Breast	71.3	0.2
Prostate ^f	50.2	-4.3*	47.3	-4.8*	Lung and Bronchus	54.8	-2.7*
Colon and Rectum	38.2	-2.3*	37.8	-2.2*	Colon and Rectum	43.6	-3.0*
Melanoma of the Skin	22.7	1.2*	27.2	1.3*	Kidney and Renal Pelvis	17.5	0.1
Urinary Bladder	20.0	-1.4*	22.0	-1.4*	Corpus and Uterus, NOS ^f	15.9	1.5*
Non-Hodgkin Lymphoma	19.6	-0.8*	20.6	-0.8*	Pancreas	15.3	0.1
Kidney and Renal Pelvis	16.3	0.4*	16.8	0.5*	Non-Hodgkin Lymphoma	14.7	-0.5*
Thyroid	15.7	1.0	16.4	0.7	Myeloma	13.8	0.3
Corpus and Uterus, NOS ^f	14.8	0.9*	15.0	-0.4	Urinary Bladder	11.8	-0.8*
Leukemia	14.1	-0.3	14.9	0.6*	Leukemia	10.8	0.3
Pancreas	13.1	0.5*	13.1	0.5*	Liver & IBD ^g	10.7	0.7
Oral Cavity and Pharynx	11.4	0.5*	12.0	0.6*	Stomach	10.1	-2.1*
Liver & IBD ^g	9.0	1.4*	8.1	1.9*	Thyroid	9.5	1.3
Stomach	7.3	-0.8*	7.1	-0.7*	Oral Cavity and Pharynx	8.5	-1.2*
	Asian/Pacific Islander		American Indian/Alaska Native ^d		Hispanic ^e		
	Rate ^b 2013-2017	APC ^c 2008-2017	Rate ^b 2013-2017	APC ^c 2008-2017	Rate ^b 2013-2017	APC ^c 2008-2017	
All Sites	302.1	-0.8*	310.1	-1.0*	All Sites	348.4	-1.1*
Breast	56.3	1.2*	42.7	-0.5	Breast	53.2	0.4
Lung and Bronchus	36.2	-1.1*	39.0	-1.1	Prostate ^f	40.7	-5.5*
Colon and Rectum	31.8	-2.5*	38.1	-1.8*	Colon and Rectum	33.7	-1.8*
Prostate ^f	25.1	-4.9*	24.3	-5.4*	Lung and Bronchus	29.0	-2.2*
Thyroid	15.8	1.2*	17.9	-0.3	Non-Hodgkin Lymphoma	18.1	-0.4*
Non-Hodgkin Lymphoma	13.5	-0.5	14.9	1.2	Kidney and Renal Pelvis	16.1	1.0*
Liver & IBD ^g	12.9	-2.2*	10.9	-3.3*	Thyroid	14.2	2.3*
Corpus and Uterus, NOS ^f	11.8	1.9*	10.6	-0.8	Liver & IBD ^g	13.7	0.6
Stomach	10.6	-2.6*	10.0	1.1	Corpus and Uterus, NOS ^f	13.1	2.1*
Pancreas	10.0	0.3	9.6	1.6	Pancreas	11.6	0.1
Urinary Bladder	8.9	-0.9*	9.3	2.3*	Urinary Bladder	11.0	-1.5*
Kidney and Renal Pelvis	8.8	0.8	8.4	-1.3	Leukemia	10.9	-0.6
Oral Cavity and Pharynx	8.5	0.4	8.1	-0.4	Stomach	10.5	-1.2*
Leukemia	8.0	-0.4	8.1	-0.8	Oral Cavity and Pharynx	6.8	-1.2*
Ovary ^{fh}	5.1	-1.0	5.7	2.9	Myeloma	6.8	0.2

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

^a Top 15 cancer sites selected based on 2013-2017 age-adjusted rates for the race/ethnic group.

^b Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^c The APC is the Annual Percent Change over the time interval.

^d Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^e Rates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^f Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^g Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^h The rates for sex-specific cancer sites are calculated using the population for both sexes combined.

ⁱ IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.

^j Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.